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Tyrosinase: A Central Regulatory
Protein for Cutaneous Pigmentation
Yoon-Soo Cindy Bae-Harboe1 and Hee-Young Park1
Cutaneous pigmentation or skin color is the body’s natural protection against sun-
induced damage. Skin color is determined primarily by melanin, a biopolymer that
is synthesized within epidermal melanocytes, packaged in cellular organelles
called melanosomes, and then dispersed to neighboring keratinocytes. The
process of melanogenesis involves numerous molecules and intracellular path-
ways that are subject to regulation by endogenous and exogenous factors.
Tyrosinase is the central and rate-limiting enzyme in melanin biosynthesis.
Therefore, elucidation of the molecules and pathways that regulate tyrosinase
levels and activity could identify target areas for the development of compounds
to decrease excessive pigmentation on one hand or induce pigmentation on the
other. The following commentary will summarize the key regulatory molecules
and pathways involved in tyrosinase function.
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Tyrosinase
The human tyrosinase gene is about 50kb
long and is composed of 5 exons and 4
introns, whereas tyrosinase messenger
RNA (mRNA) is B2kb long (genebank
access number NM_000372). The nascent
chain of the newly synthesized tyrosinase
protein is glycosylated, folded in the
endoplasmic reticulum (ER), and directed
to melanosomes, the organelles residing
within melanocytes where melanin synth-
esis takes place (Park and Yaar, 2012).
Tyrosinase spans the melanosomal
outer membrane and has three domains:
an inner melanosomal domain that con-
tains the catalytic region of the enzyme,
a short melanosomal transmembrane
domain, and a cytoplasmic domain.
The cytoplasmic domain is composed
of aB30 amino acids, and it is required
to properly traffick tyrosinase into mela-
nosomes (Beermann et al., 1995).
Two types of melanin are synthesized
within melanosomes: eumelanin and
pheomelanin. Eumelanin is dark, brown-
black, and insoluble, whereas pheomela-
nin is light, red-yellow sulfur-containing,
and soluble. Tyrosinase is the rate-limiting
enzyme in melanin biosynthesis. It cata-
lyzes the conversion of tyrosine through
oxidation to L-dihydroxyphenylalanine and
requires copper for its activation. Inhibition
of this oxidation reaction blocks melanin
synthesis (Park and Yaar, 2012). Hydro-
quinone, the most frequently used drug to
treat hyperpigmentation in the United
States, is a pseudosubstrate for tyrosinase,
thus inhibiting tyrosinase activity.
The final steps in cutaneous pigmen-
tation are the transfer of melanin-con-
taining melanosomes from melanocytes
to neighboring keratinocytes, and their
dispersion within keratinocytes. Proper
dispersal of melanosomes is required for
normal skin color and for protective
pigmentation. Melanosomes are phago-
cytosed by keratinocytes, which is faci-
litated by a seven-transmembrane G
protein–coupled receptor called protease
activated receptor-2 (PAR-2). PAR-2 is
present on the keratinocyte membrane
and is activated by serine proteases that
cleave the extracellular portion of the
receptor, exposing a new segment that
acts as a tethered (attached) ligand,
increasing keratinocyte phagocytic acti-
vity (Nystedt et al., 1994).
Regulating tyrosinase expression and/or
activity
A key transcription factor for tyrosinase
is the microphthalmia-associated trans-
cription factor (MITF) that, when upre-
gulated, increases tyrosinase expression.
MITF has also been intimately linked
with melanocyte survival (Park and
Yaar, 2012); thus, the effects of MITF
extend beyond melanogenesis per se.
Alpha-melanocyte-stimulating hormone
(a-MSH), one of the first recognized
positive regulators of mammalian pig-
mentation, upregulates the expression
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of MITF (Lerner, 1999). When a-MSH
binds to its melanocortin 1 receptor
(MC1R), the intracellular level of cAMP
is elevated through the activation of the
membrane-associated adenylate cyclase
enzyme (Figure 1). The cAMP-depen-
dent protein kinase A (PKA) enzyme
is then activated, translocates to the
nucleus, and phosphorylates the cAMP
responsive element-binding protein
(CREB). CREB then binds its DNA con-
sensus sequence CRE in the promoter
region of the MITF gene, inducing MITF
transcription.
PKC constitutes a family of at least
12 isoforms, among which PKC-b has
been shown to be involved in regulating
tyrosinase activity. PKC is a serine/threo-
nine kinase that resides as an inactive
enzyme in the cytoplasm. It is activated
by diacylglycerol (DAG), a component
of the plasma membrane that is cleaved
and released from the membrane during
the activation of certain cell surface
receptors. DAG is also released from
the membrane by UV irradiation
(Figure 1). DAG induces PKC transloca-
tion from the cytoplasm to membranes,
and PKC then catalyzes the phosphory-
lation of serine/threonine residues on
target proteins such as tyrosinase. Speci-
fically, PKC-b phosphorylates serine
residues on the cytoplasmic domain of
tyrosinase, thus activating it (Park et al.,
1999). The critical role of PKC in
melanogenesis was first suggested by the
observation that the addition of DAG, the
endogenous activator of PKC, to cultured
human melanocytes rapidly increased
their total melanin content; this increase
was blocked by a PKC inhibitor.
Moreover, topical applications of DAG
to guinea pig skin increases epidermal
melanin content (Park and Yaar, 2012).
In melanocytes, PKC-b is found in
close proximity to the melanosome mem-
brane. Whereas structural differences
among PKC isoforms may contribute to
their associations with specific sub-
cellular fractions, receptors for activated
C-kinase (RACK), which are specific for
each PKC isoform, control the transloca-
tion of PKC isoforms to specific cellular
compartments. RACK-I is the receptor for
activated PKC-b, and in human melano-
cytes the activated PKC-b/RACK-I com-
plex translocates to the melanosome
membrane to allow tyrosinase phosphor-
ylation, thus modulating tyrosinase func-
tion at the post-translational level
(Figure 1).
Diacylglycerol kinase-z
(DGK-z) presents
a novel therapeutic
target to modulate
pigmentation.
Kawaguchi et al. (this issue, 2012)
demonstrate that DGK-z is involved in
tyrosinase protein degradation at the
post-translational level. Specifically, the
investigators show that DGK-z is the
most abundant DGK isoform expressed
by human melanocytes. DGK-z, which
is phosphorylated by DAG, appears to
affect tyrosinase function independently
of PKC-b. Furthermore, inhibition of
DGK-z by small interfering RNA signifi-
cantly reduces melanin content, tyrosi-
nase activity, and tyrosinase protein
levels, whereas tyrosinase and MITF
mRNA levels remain unchanged. Conver-
sely, overexpression of DGK-z increases
the level of tyrosinase protein, but not of
tyrosinase mRNA. Protease inhibitors
partially block DGK-z’s effect, suggest-
ing that DGK is a protease or that it acts
by activating proteases. The investigators
conclude that DGK-z regulates melano-
genesis by modulating the post-transla-
tional processing of tyrosinase, speci-
fically protein degradation (Figure 1).
These findings further suggest that iso-
form-specific DGK-z inhibitor(s) have
the potential to modulate human
pigmentation.
Melanogenic inhibitors
Although the existence of endogenous
melanogenic inhibitors has been long
speculated, few of these molecules have
been identified. One group of inhibitors
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Figure 1. Signaling pathways regulating tyrosinase expression and activity. Alpha-melanocyte-stimulating
hormone (a-MSH) binding to melanocortin 1 receptor (MC1R) activates the enzyme adenylate cyclase,
increasing cAMP levels, activating the enzyme protein kinase A (PKA), and inducing gene transcription of
microphthalmia-associated transcription factor (MITF) leading to transcription of the melanogenic enzyme
tyrosinase. UV radiation (as well as cell surface receptors not shown in this figure) releases diacylglycerol
(DAG) from the cell membrane. DAG activates protein kinase C-b (PKC-b), which then phosphorylates
serine residues on tyrosinase, activating the enzyme. In addition, DAG phosphorylates diacylglycerol
kinase-z (DGK-z), which regulates tyrosinase degradation. UV also damages cellular DNA, initiating a
cascade of DNA damage responses including p53 activation, and leading to increased tyrosinase
transcription. UV irradiation, by decreasing the level of bone morphogenetic protein (BMP) receptors,
prevents BMP-4-mediated inhibition on melanogenesis. ER, endoplasmic reticulum; P, phosphate group;
RACK-I, receptors for activated C-kinase.
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includes sphingolipids, a class of mem-
brane-associated lipids that act as signal
transducers. Sphingolipids decrease mela-
nogenesis, at least partly by enhancing
MITF degradation via ubiquitin-meditated
pathways. Another melanogenic inhibitor,
bone morphogenetic protein-4 (BMP-4),
downregulates tyrosinase expression in
melanocytes, also partly via its effects on
MITF. Interestingly, physiological doses
of UV radiation, a potent melanogenic
stimulator, decrease the expresion of BMP
receptors on melanocytes (Yaar et al.,
2006), presumably eliminating BMP’s
inhibitory effect during UV-induced
tanning. Mice engineered to overexpress
the BMP antagonist noggin have a darker
coat color and a higher eumelanin-
to-pheomelanin ratio compared with
wild-type mice (Sharov et al., 2005).
UV and tyrosinase function
UV is a potent inducer of pigmenta-
tion or tanning. It increases the level of
a-MSH, DAG, and other compounds
that activate melanogensis, and conco-
mitantly it decreases the level of mela-
nogenic inhibitors such as BMP. Further-
more, UV-induced DNA damage also
appears to stimulate melanogenesis in
pigment cells (Eller et al., 1996). Interes-
tingly, the action spectrum for tanning
is virtually the same as that for the
formation of thymine dimers, and
treatment of melanocytes with agents
that act exclusively by damaging DNA
(unlike UV, which has multiple cellular
targets) also stimulates melanogenesis.
In addition, treating cells with DNA
fragments such as thymine dimers can
induce cellular responses that mimic
DNA damage responses and result in
tanning (Eller and Gilchrest, 2000).
Moreover, p53, a tumor suppressor
protein and transcription factor that is
induced and activated by UV radiation,
upregulates tyrosinase mRNA and
protein. In p53 knockout mice, UV radi-
ation stimulates melanogenesis of the
ears only minimally compared with the
far greater ‘‘tanning’’ response in p53
wild-type mice (Khlgatian et al., 2002).
Thus, tanning may be viewed as part of
a p53-mediated DNA damage–adaptive
cellular response enabling the skin to
withstand subsequent exposures to UV
radiation.
Clinical implications
Although multiple pathways that modu-
late tyrosinase expression and/or activity
have been identified, few treatment
modalities for pigmentary disorders
exist (Table 1). Some molecules inhibit
tyrosinase activity, but their effects are
largely nonspecific, and they interfere
with other proteins as well. Similarly,
few agents stimulate tyrosinase activity.
The data presented by Kawaguchi et al.,
(2012), complementing and expanding
previous work, elucidate novel mole-
cules and pathways in the pigmentary
process. Taking this work in to account,
future therapeutic modalities could be
developed to affect pigmentary disorders
and provide options for sunless tanning.
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Table 1. Current topical noninvasive treatment options for pigmentary
disorders1
Active compound Proposed mechanism of action
Hydroquinone Tyrosinase inhibitor
Tretinoin Inhibits a-MSH-mediated induction of tyrosinase and TRP-1 and stimulates
even melanosomal distribution within keratinocytes
Azelaic acid Pityrosporum ovale product that inhibits tyrosinase
Kojic acid Copper chelator fungal metabolite
Corticosteroids Nonselective suppression of melanogenesis
Octadecenedioic acid Selective suppression of melanogenesis via PPARg binding
Abbreviations: a-MSH, alpha-melanocyte-stimulating hormone; PPAR, peroxisome proliferator-
activated receptor; TRP-1, tyrosinase related protein-1.
1Chemical peels and different lasers are also used for treatment of hyperpigmentary disorders but are
beyond the scope of this commentary.
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